Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 1;32(5):870-879.
doi: 10.1093/ndt/gfw042.

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study

Aurélie Lenglet  1   2 , Sophie Liabeuf  1   3 , Najeh El Esper  4 , Sandrine Brisset  3 , Janette Mansour  5 , Anne-Sophie Lemaire-Hurtel  6 , Aurelien Mary  1   2 , Michel Brazier  1   7 , Said Kamel  1   7 , Romuald Mentaverri  1   7 , Gabriel Choukroun  1   4 , Albert Fournier  4 , Ziad A Massy  8   9   10   11
Affiliations
Randomized Controlled Trial

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study

Aurélie Lenglet et al. Nephrol Dial Transplant. .

Abstract

Background: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease.

Methods: The NICOREN multicentre, open-label and randomized study was designed to examine non-inferiority and safety of NAM when compared with sevelamer (SEV) in chronic haemodialysis patients. One hundred patients were randomized to either NAM or SEV treatment for 24 weeks. Serum biochemistry and NAM's main metabolite, N -methyl-2-pyridone-5-carboxamide (2PY), were measured to assess compliance, efficacy and safety.

Results: After 24 weeks, we observed a comparable decrease in serum phosphorus in the NAM and SEV treatment arms, from 2.1 ± 0.4 to 1.8 ± 0.5 and 2.3 ± 0.5 to 1.7 ± 0.5 mM (P = not significant), respectively. The criterion for non-inferiority was, however, not met due to a more limited number of patients being included than planned. Treatment discontinuation due to adverse events was 1.6 times higher in the NAM than in the SEV group with only 55% of study completers in the NAM arm versus 90% in the SEV arm. Thrombocytopenia was observed in four NAM-treated patients. Serum 2PY levels were comparable at baseline, but increased markedly in the NAM group, but not in the SEV group, at 24 weeks (P < 0.0001).

Conclusions: Thus, both drugs are equally effective in lowering serum phosphorus, but patients' tolerance of NAM was largely inferior to that of SEV. Extremely high 2PY levels may contribute to NAM's side effects.

Keywords: chronic kidney disease; haemodialysis; hyperphosphataemia; nicotinamide; phosphate binders.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types